Postmarketing Safety Surveillance for Typhoid Fever Vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002

Begier, Elizabeth M.; Burwen, Dale R.; Haber, Penina; Ball, Robert
March 2004
Clinical Infectious Diseases;3/15/2004, Vol. 38 Issue 6, p771
Academic Journal
Vaccines against Salmonella enterica serotype Typhi are used for prophylaxis of international travelers and have potential use as counterbioterrorism agents. The Vaccine Adverse Event Reporting System (VAERS) cannot usually establish causal relationships between vaccines and reported adverse events without further research but has successfully detected unrecognized side effects of vaccine. We reviewed reports to VAERS for US-licensed typhoid fever vaccines for the period of July 1990 through June 2002. We received 321 reports for parenteral Vi capsular polysaccharide vaccine and 345 reports for live, oral, attenuated Ty21a vaccine, with 7.5% and 5.5%, respectively, describing death, hospitalization, permanent disability, or life-threatening illness. Unexpected frequently reported symptoms included dizziness and pruritus for Vi vaccine and fatigue and myalgia for Ty21a vaccine. Gastroenteritis-like illness after receipt of Ty21a vaccine and abdominal pain after receipt of Vi vaccine, which are previously recognized events, occasionally required hospitalization. Nonfatal anaphylaxis was reported after both vaccines. VAERS reports do not indicate any unexpected serious side effects that compromise these vaccines' use for travelers' prophylaxis.


Related Articles

  • In vitro intestinal mucosal epithelial responses to wild-type Salmonella Typhi and attenuated typhoid vaccines. Fiorentino, Maria; Lammers, Karen M.; Levine, Myron M.; Sztein, Marcelo B.; Fasano, Alessio; Bimczok, Diane // Frontiers in Immunology;Feb2013, Vol. 4, Special section p1 

    Typhoid fever, caused by S. Typhi, is responsible for approximately 200,000 deaths per year worldwide. Little information is available regarding epithelium-bacterial interactions in S. Typhi infection. We have evaluated in vitro the effects of wild-type S. Typhi, the licensed Ty21a typhoid...

  • Vaccines.  // Reactions Weekly;8/6/2011, Issue 1363, p40 

    The article describes the cases of 13 patients aged 11 months to 84 years old who developed anaphylaxis or hypersensitivity reactions following vaccine injection.

  • ANTITYPHOID VACCINATION IN CHILDREN. RUSSELL, FREDERICK F. // JAMA: Journal of the American Medical Association;5/1/2013, Vol. 309 Issue 17, p1758 

    The article discusses issues related to vaccination of children against typhoid fever. It highlights the advantages of the early antityphoid vaccination on the basis of statistics in which 359 children between the ages of 2 and 16 years were vaccinated. The dosage of the antityphoid vaccine in...

  • Varicella zoster virus vaccine live.  // Reactions Weekly;2/13/2016, Vol. 1588 Issue 1, p255 

    This article presents case studies of two children, age and sex not defined, vaccinated with varicella zoster virus vaccine, a chicken pox preventive, developed anaphylactic shock and angioedema respectively on the day of the vaccination.

  • Typhoid Vaccine.  // AHFS Consumer Medication Information;Apr2018, p1 

    What is typhoid? Typhoid vaccines Who should get typhoid vaccine and when? Which people should not get typhoid vaccine or should wait? What are the risks from typhoid vaccine? What if there is a moderate or severe reaction? The National Vaccine Injury Compensation Program How can I learn more?

  • COMPARISON OF THE IMMUNOGENICITY AND SAFETY OF TWO DIFFERENT BRANDS OF SALMONELLA TYPHI VI CAPSULAR POLYSACCHARIDE VACCINE. Sabitha, P.; Prabha Adhikari, M.R.; Chowdary, Abhijit; Prabhu, Malathi; Soofi, Mohammad; Shetty, Meenakshi; Kamath, Asha; Lokaranjan, S.S.; Bangera, S.S. // Indian Journal of Medical Sciences;Apr2004, Vol. 58 Issue 4, p141 

    BACKGROUND: The recent emergence of multi-drug-resistant Salmonella strains highlights the need for better preventive measures, including vaccination. Safeand immunologic vaccines have been developed based on purified Vi polysaccharide. OBJECTIVE: To compare the immune response elicited by two...

  • A Study on Longevity of Immune Response after Vaccination with Salmonella Typhi Vi Conjugate Vaccine (PedatyphTM) in Children. CHINNASAMI, BALAJI; SADASIVAM, KANIMOZHI; VIVEKANANDHAN, ARAVINDHAN; ARUNACHALAM, PREMA; PASUPATHY, SEKAR // Journal of Clinical & Diagnostic Research;May2015, Vol. 9 Issue 5, p1 

    Background and Objectives: Owing to the limitations of the conventional polysaccharide vaccines, global efforts have been made to develop conjugated polysaccharide vaccines for typhoid. Duration of immune response induced by these vaccines is critical to define the efficacy and frequency of...

  • Mary Mallon's trail of typhoid. Carey, C. // FDA Consumer;Jun89, Vol. 23 Issue 5, p18 

    Describes the 11-year reign of typhoid epidemics in New York caused by Mary Mallon at the beginning of the twentieth century. Mallon, known in history as `Typhoid Mary,' was the first typhoid carrier identified in the US who never displayed a single symptom of the disease. Infected at least 51...

  • Winning the battle.  // FDA Consumer;Jun89, Vol. 23 Issue 5, p21 

    Describes how typhoid can be spread by pollution of public water supplies, as well as improper food preparation and handling. Advice on proper food practices; Warning to travelers on necessary precautions to avoid disease.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics